Jazz Pharmaceuticals sales and marketing update

Jazz launched Defitelio defibrotide in Germany and Austria to treat severe hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation (HSCT). Jazz plans to launch the product in 27 other European countries on a rolling basis during 2014 and 2015. Jazz, which could not be reached for details, gained the single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA through its February acquisition of Gentium S.p.A. (see BioCentury, Feb. 24). ...